Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a commercial medical
technology company that develops, manufactures and markets a family
of products based upon the Microcyn® Technology platform,
today announced that it has received new 510(k) clearance from the U.S.
Food and Drug Administration (FDA) for new dermatology indications for
Microcyn® Skin and Wound HydroGel. The Rx product, under the
supervision of a healthcare professional, Microcyn Skin and Wound
HydroGel is intended for management of wounds including itch and pain
relief associated with dermal irritation, sores, injuries and ulcers of
dermal tissue.
“We are especially excited to receive our first FDA clearance for the
Microcyn HydroGel for dermatology indications including the reduction of
itch and pain relief for troublesome skin afflictions”
Microcyn-based products, branded as Microcyn Skin and Wound Care and
Microcyn Skin & Wound HydroGel in the United States, Microdacyn60™ in
Mexico, Dermacyn™ Wound Care in Europe and China and Oxum in India, have
treated over two million patients worldwide without a single report of a
serious adverse effect.
Noridian Administrative Services LLC, which is the pricing, data
analysis and coding contractor for the Medicare program, has assigned
Medicare HCPCS code #A6248 to the Microcyn HydroGel.